Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Morgan's story began when he was taking an Uber ride in Nashville, chatting up his driver about songwriting. The newcomer had ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Belle da Costa Greene, who was JP Morgan’s librarian, became a lively fixture at Gilded Age mansions, country retreats, ...

JPMorgan Chase & Co. boosted its holdings in shares of Belite Bio, Inc (NASDAQ:BLTE – Free Report) by 7,122.7% in the 3rd ...

The bank is sourcing compute resources five to 10 years out, said Darrin Alves, CIO of infrastructure platforms.

Navi Finserv will use the funds to expand and grow its digital personal loan business, leveraging new technological advancements to strengthen its position in India's expanding digital lending sector.

Morgan Stanley (NYSE:MS) updated its outlook on Kirin Holdings Co Ltd (2503:JP) (OTC: KNBWY), raising the company's price target from ¥2,200 to ¥2,250, while sustaining an Equalweight rating on the ...

Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for ...

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, clinical-stage companies. But local biotech leaders see signs of change in ...

From volatility and geopolitics to economic trends and investment outlooks, stay informed on the key developments shaping today's markets. Whether it’s hardware, software or age-old businesses, ...